Prehabilitation Program to Improve Cardiac Reserve in High-Risk Patients Undergoing Hematopoietic Stem Cell Transplantation

Description

To assess the feasibility and preliminary effectiveness of a Cardio-Oncology Prehabilitation program in patients at high-risk of developing Cardiovascular (CV) events in improving Cardiorespiratory fitness (CRF) and reducing acute CV complications in Hematopoietic stem cell transplant (HSCT) recipients.

Conditions

Hematopoietic Stem Cell Transplant

Talk to us

Study Overview

On this page

Study Details

Study overview

To assess the feasibility and preliminary effectiveness of a Cardio-Oncology Prehabilitation program in patients at high-risk of developing Cardiovascular (CV) events in improving Cardiorespiratory fitness (CRF) and reducing acute CV complications in Hematopoietic stem cell transplant (HSCT) recipients.

Cardio-Oncology Prehabilitation Program to Improve Cardiac Reserve in High-Risk Patients Undergoing Hematopoietic Stem Cell Transplantation

Prehabilitation Program to Improve Cardiac Reserve in High-Risk Patients Undergoing Hematopoietic Stem Cell Transplantation

Condition
Hematopoietic Stem Cell Transplant
Intervention / Treatment

-

Contacts and Locations

Ann Arbor

University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States, 48109

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Adult 18 years or older
  • * Referred for HSCT evaluation
  • * Presence of least one CV risk factor at enrollment (hypertension, hyperlipidemia, atrial fibrillation, obesity, heart failure, history of coronary artery disease, diabetes)
  • * Able to ambulate unassisted
  • * Ability to understand and the willingness to sign a written informed consent
  • * Ability to use Polar Flow heart rate application
  • * Severe anemia (hemoglobin \<7 gm/dl)
  • * Untreated high-risk coronary artery disease (left main, triple vessel disease)
  • * Severe aortic stenosis
  • * Recent fracture as assessed via self-report
  • * Gross balance deficits
  • * Severe pain with basic movement
  • * Unable to ambulate unassisted or exercise
  • * NYHA class IV heart failure
  • * Adults unable to give consent, pregnant women, and prisoners are excluded from this study.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Michigan Rogel Cancer Center,

Salim Hayek, PRINCIPAL_INVESTIGATOR, University of Michigan Rogel Cancer Center

Study Record Dates

2027-08